- Home
- MGY vs TNGX Comparison
MGY vs TNGX Comparison
Compare MGY & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGY | TNGX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MGY | TNGX |
|---|---|---|
| Price | $24.97 | $29.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $30.36 | $21.78 |
| AVG Volume (30 Days) | 2.8M | ★ 4.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $1,311,845,000.00 | $62,384,000.00 |
| Revenue This Year | $14.65 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | $106.25 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $21.07 | $5.60 |
| 52 Week High | $32.76 | $34.39 |
Technical Indicators
Market Signals| Indicator | MGY | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 50.06 |
| Support Level | $21.47 | $28.13 |
| Resistance Level | $27.92 | $33.96 |
| Average True Range (ATR) | 0.77 | 1.96 |
| MACD | 0.04 | -0.48 |
| Stochastic Oscillator | 28.12 | 32.44 |
Price Performance
Historical ComparisonAbout MGY Magnolia Oil & Gas Corporation
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquids (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area of South Texas, where it targets the Eagle Ford Shale and Austin Chalk formations. It focuses on generating value for shareholders by delivering steady, moderate annual production growth resulting from its capital spending philosophy. The company operates in only one segment and derives the majority of its revenue from the sale of crude oil, natural gas, and natural gas liquids (NGLs).
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.